Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.
“Pharma, like all industries, has a responsibility to protect and enhance the environment. Our sector’s commitment takes on added significance given our role in improving people’s health.”
These words of Albert Grifols Coma-Cros, chief scientific innovation officer at Spanish firm Grifols, S.A., underline the particular responsibility...
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.
More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.
What do industry leaders anticipate as the US installs president Trump once again? Beyond the biopharma sector's biggest market, geopolitical instability has increased elsewhere: how might this affect markets and companies?
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
